“The MICHR Expanded Access program is a fantastic resource. The Expanded Access process is pretty complicated, requiring communications with the FDA, the University institutional review board, the pharmaceutical company, and lots of documentation. Early in the COVID-19 epidemic, I worked with the TEAMSS staff to obtain remdesivir for some of our first patients at Michigan Medicine. All I had to do was decide on the drug and they pretty much took care of the rest. They were available after hours and on weekends. They ‘made it happen.’””